VERZENIO
PeakNDAORALTABLETPriority Review
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERZENIO (generic name unknown) is an oral small molecule tablet approved by FDA on February 26, 2018, developed by Eli Lilly and Company. The specific mechanism of action and pharmacologic class are not provided in available data, limiting detailed description of its therapeutic mechanism. The product is currently in peak lifecycle stage, indicating established market presence and commercial maturity. Additional clinical details regarding indications and mechanism would be needed to fully characterize its position in the treatment landscape.
$0.8BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among Breast
Started Mar 2022
1,500 enrolled
The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks
Why This Matters for Your Career
Worked on VERZENIO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.